Indegene Stock Rises on Upgrade Driven by Global Pharma Outsourcing Trend
1 report, 1 independent
Updated Sep 25
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
On September 25, 2026, Indegene's stock rose nearly 5% to Rs 621.95 on the recommendation of Motilal Oswal Financial Services. The brokerage upgraded the stock to 'buy' from 'neutral' with a target price of Rs 708, implying a potential upside of nearly 17% from the prevailing market price.
From moneycontrol.com
Why it matters
The upgrade reflects the trend of global life sciences and pharmaceutical companies increasingly using external partners like Indegene to manage operational costs and accelerate go-to-market timelines. These companies often struggle to scale captive centers due to talent shortages and rising operating costs.
From moneycontrol.com